Skip to main content
OpenTrials

Clinical trial condition

KRAS P.G12C

Explore clinical trials studying KRAS P.G12C. Study availability and eligibility vary by location and protocol.

7 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

KRAS P.G12C trial results

Recruiting

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

NCT05398094

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Hospital General Universitario de Alicante Alicante, Spain
  • ICO Badalona, Hospital Germans Trias i Pujol Badalona, Barcelona, Spain
  • Hospital Universitari Quiron Dexeus Barcelona, Spain
  • Hospital Universitari Vall d' Hebron Barcelona, Spain
View all 20 locations
View Trial Details
Recruiting

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

NCT06008288

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +8 more
Locations
  • Anhui Provincial Cancer Hospital Hefei, Anhui, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Beijing Tsinghua Changgung Hospital Beijing, Beijing Municipality, China
View all 31 locations
View Trial Details
Recruiting

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

NCT05410145

Conditions
KRAS P.G12C
Locations
  • D3 Bio Investigative Site 0402 Orange, California, United States
  • D3 Bio Investigative Site 0407 Palo Alto, California, United States
  • D3 Bio Investigative Site 0404 Denver, Colorado, United States
  • D3 Bio Investigative Site 0406 Sarasota, Florida, United States
View all 52 locations
View Trial Details
Recruiting

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

NCT05288205

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +31 more
Locations
  • The First Affiliated Hospital of USTC Anhui Provincial Hospital Hefei, Anhui, China
  • Pecking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Cancer Hospital Chinese Academy Of Medical Sciences Beijing, Beijing Municipality, China
  • Beijing Tiantan Hospital, Captal Medical University Beijing, Beijing Municipality, China
View all 27 locations
View Trial Details
Active, Not Recruiting

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

NCT05673187

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Instiute Jules Bordet Brussels, Belgium
  • Le Mans - CHG Le Mans, France
  • Hôpital de Marseille Marseille, France
  • Beaumont Hospital Dublin, Ireland
View all 18 locations
View Trial Details

Related conditions